路透社：北京科兴完成全球首个甲流疫苗临床试验

2009-08-20

　　路透伦敦8月18日电---北京科兴生物制品有限公司(SVA.A) 周二表示，该公司研发的甲型H1N1流感疫苗只需接种一支就可以起到药效。
这条消息传出後，科兴公司在美国的股价顿升10%。
专家此前估计的是必须接种两支甲流疫苗才能达到免疫效果，但科兴称在接种一针後可产生良好的免疫反应。科兴是全球首个完成甲流疫苗临床试验的公司。
各国官员担心疫苗数量紧张，但如果由原来的一人接种两支改为一支将极大提高可用数量。
科兴公司表示，接种一针後的免疫性已“达到疫苗的国际标准”，且没有出现严重不良反应。
本次临床试验7月在北京启动，接种工作于8月15日完成，共有1,614名受试者。（完）
编译：杨思涵发稿：程芳

原文链接：http://cn.reuters.com/article/CNTopGenNews/idCNCHINA-362420090819

英文原文：

Sinovac says one-shot swine flu vaccine effective

Tue Aug 18, 2009 11:09am EDT

* Chinese group first to complete H1N1 vaccine trial

* Single shot means more people can be vaccinated

* Sinovac shares up 10 pct

(Writes through, adds detail, shares, background)

LONDON, Aug 18 (Reuters) - An H1N1 swine flu vaccine developed by China's Sinovac Biotech is effective after just one shot, its developer said on Tuesday.

The news boosted shares in the Chinese vaccine company by 10 percent in U.S. trading.

Until now, experts have predicted that two shots will be needed to provide swine flu immunity. But Sinovac, which is the first company worldwide to complete clinical trials for an H1N1 vaccine, said a single dose of its vaccine proved sufficient.

Leading flu vaccine makers including Sanofi-Aventis (SASY.PA), GlaxoSmithKline (GSK.L), Novartis (NOVN.VX), Baxter (BAX.N), CSL (CSL.AX) and Solvay (SOLB.BR) are racing to develop a vaccine against swine flu.

The H1N1 flu outbreak, which was declared a pandemic on June 11, has spread around the world and could eventually affect 2 billion people, according to the World Health Organisation.

Officials are concerned that supplies of vaccine will prove tight, but an ability to vaccinate people once instead of twice would stretch stocks substantially.

Sinovac said immunogenicity after one dose of its vaccine had "reached the international criteria for vaccines". There were no signs of severe adverse reactions, it added.

Its clinical trials were initiated in Beijing in July and inoculation was completed on Aug. 15, with a total of 1,614 participants over three years receiving the vaccine.

Regulators around the world are expected to start approving swine fluvaccines next month as more clinical trial results come in, allowing governments to start mass vaccination programmes from September, according to the WHO.

Medical experts say vaccines need to available quickly and in large quantities to have the greatest impact.

Vaccines arrived too late in the 1957 and 1968 flu pandemics to be of much use and flu vaccines had not been developed in the 1918 "Spanish flu" pandemic which killed an estimated 50 million. (Reporting by Ben Hirschler; Editing by David Holmes)

原文链接：http://www.reuters.com/article/marketsNews/idUSLI54489920090818